Patent Issued for Formulations of dengue virus vaccine compositions (USPTO 11883480).

Merck Sharp & Dohme LLC has been granted a patent for formulations of dengue virus vaccine compositions. The patent discusses the challenges in creating vaccines for dengue virus, which can cause a range of symptoms from mild illness to severe fever. Most vaccines tested are live attenuated vaccines, but non-replicating vaccine candidates are also being explored. The patent describes stable formulations for a live attenuated dengue vaccine, which include the addition of a cellulose derivative and a sugar alcohol or glycol to improve stability and yield after drying. These formulations aim to provide an effective and stable vaccine for preventing dengue virus infection. [Extracted from the article]